These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1066 related articles for article (PubMed ID: 1689987)

  • 1. [Antitumor candidate compounds under clinical trials in Japan].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):342-51. PubMed ID: 1689987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New anticancer drugs under clinical trials in Japan.
    Ogawa M; Ariyoshi Y
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):277-87. PubMed ID: 8040141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New anthracyclines].
    Ogawa M; Ariyoshi Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):27-33. PubMed ID: 8422185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
    Li LH; DeKoning TF; Wallace TL
    Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Models of preclinical studies of anthracyclines].
    Fizames C
    Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Structure-activity relations of antineoplastic platinum II and platinum IV coordination compounds].
    Gutsche W; Baumgart J; Schröer HP
    Arch Geschwulstforsch; 1989; 59(4):233-8. PubMed ID: 2802931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prospect for cisplatin analogs from the experimental standpoint].
    Tashiro T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1358-65. PubMed ID: 2543305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preclinical and clinical evaluation of toxicity and antitumor activity of cisplatin analogues].
    Ariyoshi Y; Ota K
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1379-85. PubMed ID: 2658826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
    MacDonald JR; Muscoplat CC; Dexter DL; Mangold GL; Chen SF; Kelner MJ; McMorris TC; Von Hoff DD
    Cancer Res; 1997 Jan; 57(2):279-83. PubMed ID: 9000568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent trend on the development of new anticancer drugs].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):425-31. PubMed ID: 8452379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of the in vivo P388 leukemia model in evaluation of antitumor activity of natural products.
    Marsh JC; Shoemaker RH; Suffness M
    Cancer Treat Rep; 1985 Jun; 69(6):683-5. PubMed ID: 4016772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The biochemical mechanisms of drug resistance to N-alkyl-N-nitrosoureas and derivatives of cis-dichlorodiammineplatinum].
    Gorbacheva LB
    Vopr Onkol; 1995; 41(2):50-1. PubMed ID: 7483435
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
    Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.
    Berners-Price SJ; Mirabelli CK; Johnson RK; Mattern MR; McCabe FL; Faucette LF; Sung CM; Mong SM; Sadler PJ; Crooke ST
    Cancer Res; 1986 Nov; 46(11):5486-93. PubMed ID: 3756897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
    Burres NS; Clement JJ
    Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K; Oka T; Morimoto M
    Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones.
    Kuśnierczyk H; Chołody WM; Paradziej-Lukowicz J; Radzikowski C; Konopa J
    Arch Immunol Ther Exp (Warsz); 1994; 42(5-6):415-23. PubMed ID: 8572901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.